Latest National Institute for Health and Clinical Excellence Stories
A SENIOR civil servant, diagnosed with terminal cancer and denied treatment with a new drug, has taken his campaign to the National Assembly calling for an end to the postcode lottery.
By JULIA HORTON RITALIN, the controversial drug for calming hyper active children, should no longer be the first treatment offered to most youngsters, according to advice out today from an influential health watchdog.
By Barry Nelson CANCER campaigner Barbara Selby has died without ever getting the advanced drug she believed could prolong her life.
Why aren't drugs which could save or prolong the lives of cancer sufferers not being licensed for NHS use? That was the tough question being faced yesterday by NICE, the National Institute for Health and Clinical Excellence, at a special meeting in Plymouth, writes Sophie Roberts.
Cancer sufferers in the South West were unhappy with the lack of answers they received at a meeting to discuss the use of life- prolonging drugs yesterday.
By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives.
BRIDGEWATER, N.J., Sept.
Professor Karol Sikora said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years.He calculated they could cost the NHS 50bn around half the current budget, which tops 100bn.The professor, who is director of Cancer Partners UK, a private provider of cancer services that works with the NHS, came up with the figures for Sky News.He said: "50bn is the equivalent to raising tax by 15p for...
By Jane Kirby THE high cost of cancer drugs could lead the NHS into "meltdown", a leading expert said today. Professor Karol Sikor a said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years.
By Helen Puttick IT is, perhaps, an unusual move; from an organisation which fought for patients to one that often faces accusations of acting against their interests.